Pfizer, Astellas' Xtandi scores Bayer-matching survival win by Kyle Blankenship Tuesday, February 11, 2020 Pfizer and Astellas' Xtandi is chasing Bayer's challenger in extending patient lives in a hard-to-treat form of prostate cancer. New data should help.
Bayer's Nubeqa wins key survival marker in prostate cancer by Angus Liu Thursday, January 30, 2020 Bayer and Orion’s Nubeqa, used on top of ADT, significantly extended non-metastatic castration-resistant prostate cancer patients' lives in phase 3.
AZ-Daiichi, Astellas, Prevnar rival and more—FiercePharmaAsia by Angus Liu Friday, January 3, 2020 Daiichi and AZ's Enhertu as well as and Astellas and Seattle Genetics' Padcev won FDA nods as China approved rivals to Prevnar and Gardasil.
Pfizer, Astellas' Xtandi matches J&J's Erleada with new FDA nod by Kyle Blankenship Monday, December 16, 2019 Xtandi is ready to take on its familiar foe with a new green light in metastatic, castration-sensitive prostate cancer
J&J's Erleada nabs new FDA nod in metastatic prostate cancer by Kyle Blankenship Wednesday, September 18, 2019 Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.
Pfizer, anemia drugs, Chinese scientists and more—FiercePharmaAsia by Angus Liu Friday, August 23, 2019 Pfizer's mature drugs plunged in China. AZ and GSK race their oral anemia drugs to Asia. Biotech leaders worry IP crackdown will hurt collaboration.
Pfizer, Astellas step in FDA fast lane toward new Xtandi use by Carly Helfand Thursday, August 22, 2019 Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.
Bayer's Nubeqa nabs fast FDA nod in prostate cancer by Angus Liu Wednesday, July 31, 2019 Analysts figure the Bayer drug's better safety profile could help it carve out market share against Pfizer and Astellas’ Xtandi and J&J’s Erleada.
With its generic spinoff cash, will Pfizer step up its buying game? by Angus Liu Tuesday, July 30, 2019 Post-Upjohn Pfizer will focus on “bolt-on opportunities” mainly in the early- to mid-stage pipeline realm, CEO Albert Bourla said.
